|
Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a
biopharmaceutical company committed to the clinical development and
commercialization of novel therapeutics to address unmet medical needs. The
Company is marketing its FDA-approved lead product,
FACTIVEŽ (gemifloxacin mesylate)
tablets. In addition to the oral tablet form, Oscient Pharmaceuticals is
developing a FACTIVE intravenous formulation for hospitalized patients.
The Company has a novel antibiotic candidate,
Ramoplanin, in advanced clinical development for the treatment of
Clostridium difficile-associated diarrhea (CDAD). The Company's preclinical
programs include an oral peptide deformylase (PDF) inhibitor series, under
preclinical development for community-based respiratory tract infections.
Job's at Oscient
Click here |
